Trimedine

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trimedine

Trimedine: Quick Facts

Property Description
Active ingredient Trimetazidine (INN)
Form Film-coated tablet (standard)
Pharmacological class Cardiovascular metabolic agent
Origin Synthetic compound
General purpose Optimizing cellular energy and function

What Type of Medicine is Trimedine?

Trimedine is the brand name used in several regions for the medicine containing the active ingredient Trimetazidine. It is classified as a pharmaceutical agent specifically designated as a cardiovascular metabolic agent. This means its primary action is focused on supporting the biochemical and energy-producing processes within heart cells. It is not a medication intended for immediate management of heart rate or blood pressure, but rather a long-term compound that supports cellular viability.

This class of medication is intended for use in situations where the heart muscle is facing energy stress. The active substance is utilized for its role in supporting metabolic efficiency within its therapeutic classification.


What is Trimedine Made Of and How is it Supplied?

The active ingredient in Trimedine, Trimetazidine, is a synthetic compound, manufactured under strict pharmaceutical guidelines to ensure high purity and consistent therapeutic effects. Unlike substances derived directly from plants or other natural sources, its origin is fully controlled, allowing for precise interaction with the body’s metabolic pathways.

Trimedine is typically supplied in the form of film-coated tablets for oral administration. This preparation is designed to deliver a specific, measured dose of the active substance systematically, making it convenient and reliable for supporting long-term metabolic health.


How Does Trimedine Differ from Other Heart Support?

Trimedine operates on a distinct principle compared to many standard cardiac treatments. While traditional drugs often work mechanically (e.g., by affecting the heart's rate or reducing resistance in blood vessels), Trimedine's focus is intracellular and supportive. It works by optimizing the way heart cells produce energy, subtly encouraging a shift in cellular fuel usage to make the cell more efficient, particularly under conditions of stress.

The medicine acts as a metabolic modulator to optimize myocardial energy utilization. This function highlights its role as a metabolic protector, providing a general, long-term benefit by enhancing the overall energy utilization of the heart muscle.

Regulatory References

  1. Trimetazidine EMA Referral

What side effects are possible with Trimedine?

Possible side effects and safety information

The safety profile for Trimetazidine is categorized according to frequency tiers defined in official regulatory documents, which group effects by the physiological system involved.

Adverse Reactions by Frequency and System

Classification System-Organ Classes Involved Examples of Listed Effects
Common (1–10%) Nervous System, Gastrointestinal, Skin Dizziness, headache, nausea, abdominal pain, diarrhea, rash, asthenia.
Rare (0.01–0.1%) Cardiac, Vascular Palpitations, extrasystoles, tachycardia, orthostatic hypotension, flushing.
Not Known Blood, Hepatobiliary, Nervous System Extrapyramidal symptoms, agranulocytosis, thrombocytopenia, hepatitis.

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile documents clinically significant adverse reactions and specific constraints for use. Serious reactions listed include extrapyramidal symptoms (such as tremor, gait instability, and restless leg syndrome), severe cutaneous reactions (e.g., Acute Generalized Exanthematous Pustulosis), and hepatitis.

The medicine is officially contraindicated in individuals with pre-existing Parkinson's disease, parkinsonian symptoms, tremors, or other related movement disorders. Use is also contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min). The label notes that the extrapyramidal symptoms are typically reversible following treatment discontinuation.

Population-Specific Safety Considerations

Specific cautions are noted for certain groups. For older adults, potential increased exposure due to decreased kidney function is a consideration, and movement disorders should be regularly monitored. Use in the pediatric population (under 18 years of age) is not recommended, as safety and efficacy data are not established in this group.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding acute Trimetazidine (Trimedine) overdose is very limited, with few specific poisoning cases documented. Consequently, the official overdose profile emphasizes immediate action and supportive care for severe symptoms.


Documented Overdose Manifestations and Actions

Overdose Scope Regulatory Documentation
Documented Manifestations Symptoms reflect severe adverse events, including Orthostatic Hypotension (a drop in blood pressure upon standing), Arterial Hypotension, and Parkinsonian symptoms (e.g., tremor, gait instability). Tachycardia and fainting are also noted potential presentations.
Emergency Action Required Seek medical advice immediately if a dose greater than the recommended amount is taken. Immediate medical attention is required upon the first sign of any severe adverse drug reaction.
Supportive Management Treatment is officially described as strictly symptomatic and supportive therapy due to the absence of a known specific antidote.

Population and Severity Considerations

The risk of increased drug exposure, which may lead to exaggerated effects or potential overexposure, is noted for elderly patients and individuals with moderate renal impairment. The regulatory framework mandates urgent consultation to manage any potential cardiovascular or neurological instability that may arise from an elevated dose.

Therapeutic Uses of Trimedine

What Trimedine Treats: Main Uses and Benefits

Trimedine (Trimetazidine) is considered relevant as an add-on therapy for the symptomatic management of stable angina pectoris, which is defined by recurring episodes of symptoms related to physical discomfort in the chest.


Managing Recurrent Angina Symptoms and Chest Discomfort

Trimedine is commonly used for the symptomatic management of stable angina pectoris, addressing conditions characterized by recurrent or episodic manifestations. This medicine is applied in contexts where additional symptomatic support is needed, and may assist with reducing the frequency and intensity of anginal attacks, contributing to easing the overall symptom load.


Improving Functional Capacity and Supportive Adjunct

The medication is relevant in clinical settings marked by symptoms that interfere with daily functioning and create noticeable physiological strain. It is generally used as an add-on therapy when symptoms persist despite conventional first-line anti-anginal drugs, and provides supportive relief in certain cases of Chronic Heart Failure presenting with Left Ventricular Dysfunction, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Angina
This medicine is generally used to support a patient's capacity for effort and is relevant for easing the overall burden of chest discomfort linked to physical activity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trimedine?

Trimedine (Trimetazidine) has specific population eligibility rules defined by regulatory authorities, restricting its use to adults who meet specific health criteria.


Absolute Contraindications (Must Not Use)

Use is strictly prohibited for patients with a known hypersensitivity to the medicine. It is also contraindicated for individuals with Parkinson’s disease, any parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders. Furthermore, patients with severe renal impairment (creatinine clearance < 30 mL/min) must not use this medicine, due to the risk of drug accumulation.


Restricted and Not Recommended Populations

The medicine is not recommended for children and adolescents under 18 years of age because safety and efficacy have not been established in this population. Caution is required when prescribing to older adults (over 75 years) and patients with moderate renal impairment (creatinine clearance 30 -60 mL/min). Use is avoided during pregnancy and not recommended during breastfeeding, as a risk to the infant cannot be excluded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Trimetazidine (Trimedine) is characterized by a minimal burden of documented drug-drug interactions. Authoritative government health agencies have determined that no clinically relevant interaction patterns have been identified with other medicinal products. This minimal profile is structurally defined by the absence of prohibitions or specific cautions regarding co-administration.

Interaction Type Official Regulatory Statement
Contraindicated Combinations No medicinal products are formally listed as prohibited for co-administration due to interaction risk.
Metabolic Interactions Not documented as a clinically significant inhibitor or substrate of major cytochrome P450 (CYP) enzymes.
Timing Separation Rules No mandatory timing requirements are necessary for co-administration with other medicines.
Drug-Food Interactions Official labeling indicates the medicine can be taken with meals without restriction.

Population-Specific Pharmacokinetic Consideration

The only significant constraint documented in official product information relates to the clearance of the medicine itself. Since Trimetazidine is largely cleared by the kidneys, patients with moderate renal impairment (creatinine clearance between 30 and 60 mL/min) and elderly patients over 75 years old will experience increased plasma exposure of the active substance. This pharmacokinetic observation is a formal regulatory note, resulting from the age-related decrease in renal function that reduces the body’s ability to clear the medicine. The overall interaction structure confirms that this medicine does not affect or is not affected by other drugs in a manner requiring specific constraints.

Mechanism of Action

How Trimedine Works: Mechanism of Action

Trimedine (Trimebutine) acts via a multi-target mechanism primarily confined to the gastrointestinal (GI) tract.

Peripheral Opioid Receptor Modulation

Trimedine and its active metabolite function as agonists on peripheral mu, kappa, and delta opioid receptors located on neurons of the enteric nervous system (ENS). By modulating these G-protein coupled receptors, the drug influences the release of local neurotransmitters, resulting in modulation of signal transduction between nerve endings and muscle cells.


Direct Ion Channel Control and Neural Antagonism

Simultaneously, the drug exerts a direct biophysical effect on GI smooth muscle cells by modulating voltage-gated Ca^2+ and K^+ channels. This alters the cell's membrane potential and subsequent contractions, resulting in altered membrane excitability that influences the pattern and pace of propulsive contractions within the digestive tract. Furthermore, Trimedine exhibits secondary, non-selective antagonism of muscarinic acetylcholine receptors ( mAChRs), limiting excessive cholinergic stimulation and contributing to a modulatory effect on contractile activity.

Dosage and Administration Information

How Trimedine is Used: Administration Guidelines

Trimedine, containing the active substance trimetazidine, is administered via the oral route using a Modified-Release (MR) tablet formulation, most commonly at a 35 mg strength. The standard adult regimen for this formulation involves taking one 35 mg tablet twice daily, with one dose in the morning and one in the evening.

Administration is structured around food intake, requiring the tablet to be taken with meals to ensure consistency in its release profile and absorption. The medicine is designed for a long-term supportive role, with treatment benefit typically assessed after an initial three-month period to confirm continued appropriateness.

Administration Protocols and Constraints

Instruction Standard Requirement
Administration Route Oral, using the tablet form.
Standard Frequency Twice daily (BID), typically morning and evening.
Timing with Food Must be taken with meals.
Tablet Handling The tablet must be swallowed whole and should not be crushed, broken, or chewed.

Specific dose adjustments are applied for certain patient populations. For individuals with moderate renal impairment (creatinine clearance between 30 and 60 ml/min), the dose is reduced to one 35 mg tablet taken only once daily in the morning. In the event that a dose is missed, the standard procedure is to take the next scheduled dose at the usual time and avoid taking two doses together.

Recent Clinical Evidence

Trimedine: Overview of Research Evidence

This section describes the types of clinical studies that have examined Trimedine for its main uses, focusing only on the structure of the evidence, what was observed in these studies, and what remains uncertain without offering any medical advice or interpretation of results.


Evidence for Use in Chronic Ischemic Cardiac Conditions

Research into the use of Trimedine for Chronic Ischemic Cardiac Conditions includes randomized controlled trials (RCTs) and systematic reviews. These studies typically examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

In these studies, researchers monitored the measurements taken during exercise capacity tests and recorded changes in the frequency of specific symptoms. The findings describe patterns observed in the studies where short-term changes were measured during the study period in the studied patient cohorts. Long-term outcomes are not fully established, and there is limited information for long-term outcomes that measure overall systemic changes.


Evidence for Use in Specific Vertigo and Tinnitus Conditions

Research into Trimedine’s use for Specific Vertigo and Tinnitus Conditions includes smaller-scale, placebo-controlled trials. These studies were studied for their potential to influence outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort.

Studies monitored how symptoms changed in the observed populations, using scales to measure the intensity and frequency of balance issues. The findings describe patterns observed in the studies where short-term changes were measured during the study period in the studied patient cohorts. Comparative evidence is lacking between Trimedine and many other approaches. The evidence base for both indications is often limited by follow-up durations.


What Is Still Uncertain About Trimedine Research

Despite the existing evidence, several key areas of uncertainty remain. Long-term effects are not fully established, as there is limited information for long-term outcomes that measure the sustained duration of observed changes. Sample sizes were modest in many of the studies, and subgroup findings are uncertain. Research provides context but does not determine whether an individual will respond similarly over extended time periods.

Frequently Asked Questions (FAQ)

Common questions about Trimedine (FAQ)

Q: Are there any foods or drinks I should avoid while on Trimedine?

Official regulatory documents generally state that no clinically significant drug-food interactions have been identified. However, because the medicine can cause dizziness or drowsiness, some patient safety information advises caution regarding alcohol consumption, as this may worsen those effects.

Q: Is it safe to take Trimedine if I have high blood pressure?

Trimedine is not a medicine intended to manage blood pressure directly, and it does not have known significant haemodynamic effects (changes in blood pressure or heart rate) in clinical studies. However, official product information lists a fall in blood pressure when standing up (orthostatic hypotension) as a Rare side effect.

Q: Can older people safely use Trimedine?

Caution is advised for older adults, particularly those over 75 years old. This is because age-related decline in kidney function may increase the body's exposure to the drug. For this reason, official guidelines recommend monitoring older adults for movement disorders while the medicine is being used.

Q: What happens if I miss a dose of Trimedine?

Regulatory guidance on missed doses is to take the next scheduled dose at the usual time. The regulatory guidance instructs the patient to avoid taking two doses together to make up for the missed one.

Q: Can I take Trimedine with my daily vitamin supplements?

Official information indicates a low interaction risk, as no clinically relevant interactions have been identified with other medicinal products. The drug is also not documented as significantly affecting the major liver enzymes that break down other substances, suggesting a low interaction risk.

Q: Is Trimedine known to cause drowsiness or affect driving?

Yes, regulatory information notes that cases of dizziness and drowsiness have been observed, which may affect the ability to drive or operate machinery. Official documentation notes that patients must be aware of how the medicine affects them, particularly regarding driving.

Q: How long can a person usually stay on Trimedine?

Trimedine is designed for a long-term supportive role in the management of its approved conditions. The official treatment protocol often involves assessing the benefit of the medicine after an initial period of about three months to confirm continued effectiveness.

Q: Can people with liver issues use Trimedine?

Official product information notes the rare possibility of liver disease, such as hepatitis, as a side effect. While non-severe liver impairment is not listed as a formal contraindication, some sources advise caution in patients with a history of liver conditions.

Q: Is Trimedine safe for pregnant or breastfeeding women to use?

The medicine should be avoided during pregnancy due to a lack of clinical data to rule out risks. Similarly, breastfeeding is not recommended during treatment because the active substance may be passed to the infant.

Q: What are the signs of a serious side effect from Trimedine I should watch for?

Serious adverse reactions noted in regulatory information include the development of movement disorders, such as tremor, gait instability, or a shuffling walk. Signs that are noted in regulatory information include severe skin reactions (like a widespread rash with blistering) or liver disease (such as unusual nausea or yellowing of the skin or eyes).

Q: Are there different strengths of Trimedine available?

The most common and widely discussed formulation is the 35 mg Modified-Release (MR) tablet. However, the medicine may also be available in other forms in various regions, such as a 20 mg tablet or a liquid oral solution.

Q: Can children take Trimedine safely?

The use of Trimedine is not recommended in children and adolescents under 18 years of age. This restriction is based on the fact that the safety and efficacy of the medicine have not been established in this younger population.

Q: Is it normal for Trimedine to be taken multiple times a day?

The standard adult regimen is typically one tablet taken twice daily, in the morning and evening. This frequency is consistent with the tablet being formulated as a Modified-Release (MR) product, designed to provide consistent medication levels in the body throughout the day.

Q: Can I crush or split my Trimedine tablet?

Official guidance mandates that the tablet must be swallowed whole and should not be crushed, broken, or chewed. This is essential to preserve the proper functioning of the Modified-Release formulation.

Q: Is it normal to feel a little dizzy when first starting Trimedine?

Dizziness is officially listed as a Common side effect, meaning it may affect up to 1 in 10 users. While regulatory information does not specify the timing, Common effects are often reported when first starting or adjusting treatment.

Q: Does Trimedine affect sleep patterns?

Yes, sleep disorders, including difficulty in sleeping (insomnia) or excessive drowsiness, have been reported in post-marketing experiences. However, the true frequency of these effects cannot be estimated from the currently available official data.

Q: Why is Trimedine used to treat so many different symptoms?

The medicine is classified as a metabolic agent, meaning its primary action is to optimize how cells—particularly heart cells—produce energy and function under stress. This foundational cellular benefit is thought to support its use across different conditions involving energy or functional imbalance.

Q: How soon after stopping Trimedine do the effects wear off?

The drug's elimination half-life is around 7 hours in healthy adults, which relates to the time required for its effects to decrease substantially. This clearance process is also dependent on the patient's renal function.

Q: Is a headache a common side effect of Trimedine?

Yes, headache is officially listed as a Common side effect. This means that based on clinical data, a headache may be experienced by up to 1 in 10 users.

Q: Could Trimedine affect my appetite?

A loss of appetite has been reported in post-marketing experience with a frequency that is currently unknown. It is also listed as a symptom that may be associated with the rare side effect of liver disease.

Q: Can people with a history of allergies take Trimedine?

The medicine is strictly contraindicated, meaning it must not be used, by individuals with a known hypersensitivity (severe allergic reaction) to the active substance, Trimetazidine, or any other ingredient in the tablet.

Q: How does Trimedine affect the central nervous system?

The medicine affects the nervous system, potentially causing common side effects like dizziness and headache. Critically, it is contraindicated in patients with Parkinson’s disease and can cause serious movement disorders, which are effects on the nervous system.

Q: Has Trimedine been approved by [relevant major health authority, e.g., FDA/EMA]?

Yes, the active ingredient, Trimetazidine, is authorized and subject to regulatory oversight by major governmental bodies such as the European Medicines Agency (EMA) and the MHRA in the UK, among others, and is approved for use in many regions globally.

Q: Do most people tolerate Trimedine well?

Regulatory data classifies the most commonly reported side effects, such as dizziness, headache, nausea, and abdominal pain, as Common, affecting up to 10% of users. The number of people who tolerate the medicine without these issues is determined by these official frequency bands.

How should Trimedine be stored and disposed of?

How to Store and Dispose of Trimedine?

The storage and disposal of Trimetazidine (Trimedine) are governed by specific regulatory requirements to maintain product stability and ensure environmental safety.


Official Storage Conditions

Requirement Specific Condition
Temperature Limit Store at a temperature not exceeding 30 C.
Protection Keep in a cool and dry place, protected from light and heat.
Container Rule Must be kept in a tightly closed container.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Official instructions mandate that any unused medicinal product or waste material must be disposed of in accordance with local requirements. It is explicitly directed that the product should not be emptied into drains or water courses to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trimedine found in:

A-Z Index: